Praveen Tipirneni is the founder of Morphic Therapeutic. Morphic Therapeutic has raised $3.2B in total funding. Latest round: Series B.
Praveen Tipirneni is the President and CEO of Morphic Therapeutic, a Waltham, Massachusetts-based biotechnology company. Morphic Therapeutic focuses on developing oral, small-molecule formulations targeting integrin cell-surface receptors, which are linked to inflammation, fibrosis, oncology, and cardiometabolic diseases. The company raised $80 million in a Series B round in 2018 to advance its lead integrin-targeting programs and move additional programs into clinical trials.
Full founder directory · Investor directory · Company funding database · Fundraising library